SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000886163-24-000026
Filing Date
2024-05-07
Accepted
2024-05-07 07:36:30
Documents
13
Period of Report
2024-05-06
Items
Item 1.01: Entry into a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K lgnd-20240506.htm   iXBRL 8-K 27880
  Complete submission text file 0000886163-24-000026.txt   154932

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT lgnd-20240506.xsd EX-101.SCH 1911
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT lgnd-20240506_lab.xml EX-101.LAB 22783
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT lgnd-20240506_pre.xml EX-101.PRE 13053
16 EXTRACTED XBRL INSTANCE DOCUMENT lgnd-20240506_htm.xml XML 2728
Mailing Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121
Business Address 3911 SORRENTO VALLEY BLVD SUITE 110 SAN DIEGO CA 92121 858-550-7500
LIGAND PHARMACEUTICALS INC (Filer) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33093 | Film No.: 24919637
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)